Ardelyx

ARDX

Market cap $1.36B

WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company presented data, including results from the first real-world study of XPHOZAH, at American Society of Nephrology's Kidney Week, currently underway in Houston.

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 4:30 pm GMT/11:30 am ET.

Ardelyx (ARDX) is rated BUY, driven by strong Q3 2025 results, led by IBSRELA's explosive growth and resilient pipeline. IBSRELA revenue surged 92% YoY, offsetting XPHOZAH's Medicare-related decline; management raised 2025 guidance and outlined long-term peak sales targets. ARDX maintains a robust cash position, near-breakeven operations, and strategic patent protection, supporting ongoing commercial and pipeline development.

Ardelyx shares surged on Friday after strong Q3 results and positive guidance, validating patience during previous setbacks. The company demonstrated resilience, with recent financial performance supporting what should be renewed investor confidence in ARDX. Updated analysis highlights Ardelyx's improving fundamentals and potential for further upside following the latest quarterly report.

WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that President and CEO, Mike Raab will participate in a fireside chat at the Wedbush Rewind ASN 2025 Conference on Monday, November 10, 2025 from 11:30 a.m. to 12:00 p.m. ET.

Ardelyx, Inc. ( ARDX ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Michael Raab - President, CEO & Director Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Christopher Raymond Joohwan Kim Roanna Ruiz Dennis Ding Thomas Matthew Caufield - H.C. Wainwright & Co, LLC, Research Division Joseph Thome - TD Cowen, Research Division Julian Harrison - BTIG, LLC, Research Division Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division Daz Patel Presentation Operator " Caitlin Lowie Vice President of Corporate Communications & Investor Relations " Michael Raab President, CEO & Director " Eric Foster Chief Commercial Officer " Justin Renz Chief Financial & Operations Officer " Christopher Raymond " Raymond James Joohwan Kim " Citi Roanna Ruiz " Leerink Partners Dennis Ding " Jefferiesruiz Thomas " Wedbush Securities Matthew Caufield H.C.

While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to break-even earnings per share a year ago.

Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA ® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected to be between $270-275 million XPHOZAH ® Q3 revenue of $27.4 million, up 9% compared to Q2 2025 Company announces pipeline program for next-generation NHE3 inhibitor; Potential application across multiple therapeutic areas Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2025 and provided a corporate update.

IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstrates effectiveness of IBSRELA in reducing abdominal bloating for patients with IBS-C Analysis of electronic health records suggests IBSRELA may reduce burden to healthcare system WALTHAM, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company presented data supporting the company's first-in-class retainagogue, IBSRELA® (tenapanor) at the American College of Gastroenterology's (ACG) Annual Scientific Meeting, now underway in Phoenix.